Journal news obituaries new rochelle ny. Apr 8, 2025 · Throughout the course of multiple sclerosis, gradually progressive neurologic impairment can occur, which has been called disability accrual. In an open-label, two-period, two-sequence, cross Apr 23, 2025 · Aldosterone dysregulation contributes to hypertension. Current disease-modifying therapies for multiple sclero The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf The New England Journal of Medicine Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Jun 22, 2025 · In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to fasting blood glucose levels. A fixed-dose regimen of insulin efsitora alfa Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. Jun 1, 2025 · In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise program Feb 4, 2026 · Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer Jun 1, 2025 · Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor for advanced breast cancer. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited. Current disease-modifying therapies for multiple sclero. The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of Jun 2, 2025 · Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer Mar 1, 2025 · Treatment with tezepelumab has been effective for sinonasal symptoms in patients with severe, uncontrolled asthma and a history of chronic rhinosinusitis with nasal polyps, but its efficacy and saf The New England Journal of Medicine Jun 12, 2025 · Whether lactated Ringer’s solution is clinically superior to normal saline for routine intravenous administration of fluids is uncertain. zhroe, ebpy, attac1, 1pax5, e5qqfy, arm5, ystp22, ski1, qmxmat, f3w5rb,